NEWS

• Signant Health Acquires Ametris To Create An End-To-End eCOA And Wearables Platform

  Signant Health announced its acquisition of Ametris (formerly ActiGraph), a global digital health solutions provider. This strategic acquisition unites industry-leading eCOA solutions with validated, wearable-derived digital outcome measures.

• Avance Clinical Announces Asia Pacific And Mainland China Expansion Ahead Of BIO International Convention 2026

  Avance Clinical, the Australian-headquartered global Contract Research Organization (CRO) for biotechs, today announced a significant expansion of its Asia Pacific and China operations, reinforcing its position as the leading CRO partner for international biotech companies seeking access to the region’s diverse patient populations, scientific infrastructure, and accelerated clinical trial timelines.

• The Ottawa Hospital's Biotherapeutics Manufacturing Centre (BMC) Makes Breakthroughs Break Through As Boreal Biomanufacturing

  The Ottawa Hospital’s Biotherapeutics Manufacturing Centre (BMC), a facility that has developed more than 20 distinct cell- and virus-based products for human clinical trials in Canada, the United States, Europe and Asia, is becoming Boreal Biomanufacturing (Boreal). 

• Suvoda Patient App Earns "Best Patient Relationship Management Solution" In 2026 MedTech Breakthrough Awards Program

  MedTech Breakthrough, an independent market intelligence organization that recognizes the most innovative companies, technologies, and products in the global digital health and medical technology market, today announced that Suvoda, a global leader in clinical trial technology, has been selected as winner of the “Best Patient Relationship Management Solution” award in the 10th annual MedTech Breakthrough Awards program.

• Quotient Sciences Advances AI-Designed Drug Product Into Clinical Development
• Paradigm Health Announces Collaboration With The FDA To Transform Regulatory Review Of Clinical Trial Data

  The initiative will be implemented in two trials, using Paradigm Health’s integrated technology platform to accelerate FDA review.

• Inside Information: Nanoform Signs First Exclusivity Agreement For Ultra-High Concentration Subcutaneous Delivery

  Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), the medicine performance‑enhancing company, today announced that it has signed an exclusivity agreement with a U.S. biopharmaceutical company (Nasdaq listed, Mcap USD 1Bn+) for the application of Nanoform’s proprietary biologics nanoparticle technology to support the development of differentiated subcutaneous biologic medicines.

• Suvoda Announces Agentic RTSM, Enabling The Reduction Of Clinical Trial Startup Timelines By Up To 80%

  The next evolution of Suvoda IRT is designed to accelerate study builds and change orders, elevate user experience, and deliver intelligent insights

• Signant Health Enters Definitive Agreement To Acquire Ametris

  Signant Health, the evidence generation company, today announced that it has entered into a definitive agreement to acquire Ametris (formerly ActiGraph), a global digital health solutions provider, subject to customary regulatory processes and approvals and closing conditions.

• Crucial Data Solutions Expands TrialKit AI With Study Simulation And Validation Capabilities
• AI HealthTech Pioneer Biorce Opens U.S. Offices In Austin To Accelerate Global Expansion

  Biorce expands its U.S. footprint and AI R&D operations by opening a new office in Austin, Texas this week. In Europe, Biorce is already rapidly transforming how Phase I–III clinical trials—up to market approval—are developed.

• Signant Health Appoints Specialist Physician And Clinical Research Expert Dr. Graham C. Ellis As Clinical Vice President To Strengthen Metabolic Disease And Diabetes Trial Capabilities

  Signant Health, the leader in evidence generation for modern clinical trials, announced today the appointment of Dr. Graham C. Ellis as Clinical Vice President. With more than 25 years of experience as a specialist physician and clinical researcher in diabetes, endocrinology, and metabolic disease, Dr. Ellis brings extensive scientific depth and a distinguished track record as a Principal Investigator across more than 150 international Phase 2–4 clinical trials. His appointment strengthens Signant’s capabilities in supporting sponsors developing treatments in metabolic disease, obesity, and related therapeutic areas.

• Suvoda Advances Clinical Trial Financial Planning With Support For Complex Multi-Payee Budgets

  Suvoda, a clinical trial technology company, today announced new split budget functionality within its Budgeting & Benchmarking solution, expanding how sponsors and CROs can manage complex site budget development across global studies and helping to accelerate the up-front work of clinical trials.

• Suvoda Named "Most Innovative Clinical Trial Technology Firm Of 2026"

  Suvoda, a global leader in clinical trial technology, has been recognized as the Most Innovative Clinical Trial Technology Firm of 2026 in the Global Excellence Awards presented by Global Health & Pharma magazine. This accolade recognizes Suvoda’s leadership in advancing clinical trial software solutions that empower sponsors, CROs, patients, and study sites with streamlined operations and real-time insights.